To date, several anti-VEGF drugs, alone or in combination with chemotherapy, have shown promising clinical anti-cancer efficacy in colorectal [23], breast [24], ovarian [25] and glioma [26], validating the potential role of VEGF pathway inhibitors as an emerging therapy for cancer. The gene discussed is VEGFA; the disease is glioma.